Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Locally Advanced or Metastatic Unresectable Urothelial Cancer 1

Interventions

Gemcitabine 29 pembrolizumab 20 Cisplatin 20 Magnetic Resonance Spectroscopy 17 Specimen Handling 16 Mitomycin 10 enfortumab vedotin 9 durvalumab 9 Cystoscopy 9 avelumab 8 Nivolumab 8 Fluorouracil 8 Carboplatin 8 Radiation 7 Cystectomy 6 atezolizumab 5 Transurethral Resection of Bladder 5 Radiotherapy 5 Mitozytrex 5 Docetaxel 5 Biopsy 5 tremelimumab 4 sacituzumab govitecan 4 erdafitinib 4 dehydroftorafur 4 Platinum 4 Immunoglobulin G 4 Disulfides 4 1,2-diaminocyclohexaneplatinum II citrate 4 disitamab vedotin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × vinflunine × 90 days × Clear all

NCT07419295 2026-05-29

TroFuse-031

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡